Distilling the Past – Envisioning the Future

  • Richard J. Ablin
  • Malcolm D. Mason
Part of the Cancer Metastasis – Biology and Treatment book series (CMBT, volume 10)


Prostate Cancer Androgen Receptor Prostate Cancer Cell Zoledronic Acid Human Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Penson DF, Albertsen PC. The natural history of prostate cancer. This volume, 2008.Google Scholar
  2. 2.
    Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003, 30:219–6.PubMedGoogle Scholar
  3. 3.
    Thompson IM, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG. The influence of finasteride on the development of prostate cancer. N Eng J Med 2003, 349:215–4.Google Scholar
  4. 4.
    Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the united states: Implications of various definitions for abnormal. J Natl Cancer Inst 2005, 97:1132–37.PubMedGoogle Scholar
  5. 5.
    Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et. A. Prostate testing for cancer and treatment (protect) feasibility study. Health Technol Assess 2003, 7:1–88.PubMedGoogle Scholar
  6. 6.
    Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977–84.PubMedGoogle Scholar
  7. 7.
    Maitland NM. The search for genes which influence prostate cancer metastasis: A moving target. This volume, 2008.Google Scholar
  8. 8.
    Hendrix MJC, Luo J, Seftor E, Sharma N, Heidger P, Cohen M et al. Epithelial-mesenchymal molecular interactions in prostatic tumor cell plasticity. This volume, 2008.Google Scholar
  9. 9.
    Davies G, Harrison G, Mason, M. β-Catenin, its binding partners, signalling mechanisms: Implications in prostate cancer. This volume, 2008.Google Scholar
  10. 10.
    Kuefer R, Hofer MD, Zorn CSM, Engel O, Volkmer BG, Juarez-Brito MA et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 2005, 92:2018–3.PubMedGoogle Scholar
  11. 11.
    Yegnasubramanian S, Nelson WG. CpG hypermethylation changes during prostate cancer progression and metastasis, pp. 45–79. In: DNA Methylation, Epigenetics and Metastasis. Esteller M, ed., Dordrecht: Springer, 2005.Google Scholar
  12. 12.
    Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004, 64:825–9.PubMedGoogle Scholar
  13. 13.
    Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004, 64:6854–57.PubMedGoogle Scholar
  14. 14.
    Xing N, Qian J, Bostwick D, Bergstrahl E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001, 48:7–15.PubMedGoogle Scholar
  15. 15.
    Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG. The polycomb group EHZ2 is involved in progression of prostate cancer. Nature 2002, 419:624–9.PubMedGoogle Scholar
  16. 16.
    Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JI, Laciak R et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 2004, 145:3961–70.PubMedGoogle Scholar
  17. 17.
    Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maltra A et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707–12.PubMedGoogle Scholar
  18. 18.
    Lin B, Ferguson C, White JT, Wang S, Vessala R, True LD et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999, 59:4180–84.PubMedGoogle Scholar
  19. 19.
    Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005, 388:967–72.PubMedGoogle Scholar
  20. 20.
    Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: A novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002, 62:251–61.PubMedGoogle Scholar
  21. 21.
    Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. Phosphorylation of akt (SER473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004, 64:5232–36.PubMedGoogle Scholar
  22. 22.
    Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004, 4:499–511.PubMedGoogle Scholar
  23. 23.
    Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami H-O et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from the cancer prostate in sweden study. Cancer Res 2004, 64:2918–2.PubMedGoogle Scholar
  24. 24.
    Li L. Regulation of innate immunity signaling and its connection with human diseases. Curr Drug Targets Inflamm Allergy 2004, 3:81–6.PubMedGoogle Scholar
  25. 25.
    Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009–14.PubMedGoogle Scholar
  26. 26.
    Eccles SA, Paon L. Breast cancer metastasis: When, where, how. Lancet 2005, 365:1006–07.PubMedGoogle Scholar
  27. 27.
    Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: Role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003, 63:2306–11.PubMedGoogle Scholar
  28. 28.
    Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004, 6:43–54.PubMedGoogle Scholar
  29. 29.
    Kacani L, Wurm M, Schennach H, Braun I, Andrle J, Sprinzl GM. Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol 2003, 39:672–9.PubMedGoogle Scholar
  30. 30.
    Kubsch S, Graulich E, Knop J, Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: Association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by P27KIP1. Eur J Immunol 2003, 33:1988–97.PubMedGoogle Scholar
  31. 31.
    Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J et al. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001, 18:931–42.PubMedGoogle Scholar
  32. 32.
    Satoh T, Timme TL, Gdor Y, Miles BJ, Amato RJ, Kadmon D et al. Immuno-gene therapy for metastatic prostate cancer. This volume, 2008.Google Scholar
  33. 33.
    Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975, 15:617–31.PubMedGoogle Scholar
  34. 34.
    Jiang WG. Polyunsaturated fatty acid and prostate cancer metastasis. This volume, 2008.Google Scholar
  35. 35.
    Bidoli R, Talamini R, Bosetti C, Negri E, Maruzzi D, Montella M et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 2005, 16:152–57.PubMedGoogle Scholar
  36. 36.
    Kelavkar UP. Cohen C. 15-Lipoxygenase-1 expression upregulated, activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 2004, 6:41–52.PubMedGoogle Scholar
  37. 37.
    Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 2003, 62:21–6.PubMedGoogle Scholar
  38. 38.
    Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003, 63:1975–80.PubMedGoogle Scholar
  39. 39.
    Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D et al. Castration induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003, 63:3575–84.PubMedGoogle Scholar
  40. 40.
    Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. Erbb-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003, 22:781–96.PubMedGoogle Scholar
  41. 41.
    Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 1997, 15:1115–20.PubMedGoogle Scholar
  42. 42.
    Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795–805.PubMedGoogle Scholar
  43. 43.
    Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Kitamura H et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003, 56:280–6.PubMedGoogle Scholar
  44. 44.
    Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003, 100:5124–29.PubMedGoogle Scholar
  45. 45.
    Lee SO, Lou W, Hou M, deMiguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003, 9:370–76.PubMedGoogle Scholar
  46. 46.
    Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999, 26:407–21.PubMedGoogle Scholar
  47. 47.
    Yeh S, Lin HK, Kang Thin HYTH, Lin MF, Chang C. From HER2/neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96:5458–63.PubMedGoogle Scholar
  48. 48.
    Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the akt pathway. Cancer Res 2000, 60:6841–45.PubMedGoogle Scholar
  49. 49.
    Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the california cancer consortium screening and phase II trial. Cancer 2004, 100:2125–31.PubMedGoogle Scholar
  50. 50.
    Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003, 532:253–68.PubMedGoogle Scholar
  51. 51.
    de Bono J, Bellmunt J, Droz J, Miller K, Zugmaier G, Sternberg C. An open label, phase II, multicenter, study to evaluate the efficacy, safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC). J Clin Oncol 2005, 23(Suppl):4609.Google Scholar
  52. 52.
    Shelley M, Bennett C, Nathan D, Sator O. Hormone treatment for prostate cancer. This volume, 2008.Google Scholar
  53. 53.
    Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000, 88:3009–14.PubMedGoogle Scholar
  54. 54.
    Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer; initial results of the medical research council trial. Br J Urol 1997, 79:235–46.Google Scholar
  55. 55.
    Sciarra A, Casale P, Colella D, Di Chiro C, Di Silverio F. Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy. Scand J Urol Nephrol 1999, 33:211–6.PubMedGoogle Scholar
  56. 56.
    Song J, Pang S, Lu Y, Yokoyama KK, Zheng J-Y, Chiu R. Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promotor. Cancer Res 2004, 64:7661–63.PubMedGoogle Scholar
  57. 57.
    Kei Kwok W, Ling M-T, Lee T-W, Lau TCM, Zhou C, Zhang X et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005, 65:5153–62.Google Scholar
  58. 58.
    Newman RM, Zetter BR. Cell cycle regulation. This volume, 2008.Google Scholar
  59. 59.
    Oudard S, Legrier ME, Boye K, Bras-Goncalves R, De Pinieux G, De Cremoux P et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003, 169:1729–34.PubMedGoogle Scholar
  60. 60.
    Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 2003, 30:49–55.PubMedGoogle Scholar
  61. 61.
    Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F et al. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999, 161:674–79.PubMedGoogle Scholar
  62. 62.
    Huang S, Pettaway CA, Bucana CD, Fidler IJ. Blockage of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 2001, 20:4188–97.PubMedGoogle Scholar
  63. 63.
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345–57.PubMedGoogle Scholar
  64. 64.
    Hoffman RM. Orthotopic metastatic mouse models of prostate cancer. This volume, 2008.Google Scholar
  65. 65.
    Clarke N, Fleisch H. The biology of bone metastases from prostate cancer and the role of bisphosphonates. This volume, 2008.Google Scholar
  66. 66.
    Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004, 64:6082–90.PubMedGoogle Scholar
  67. 67.
    Adis R&D Insight. NF-kappa B inhibitors in development. (file://C:\ WINDOWS\ Temporary%20Internet%20Files\Content.IE5\CKO62R50\NF_Kappa_ inhi_Drugs.htm) Accessed August 31, 2005.Google Scholar
  68. 68.
    Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997, 57:524–31.PubMedGoogle Scholar
  69. 69.
    Buttyan R, Sawezuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of c-myc protooncogene in high-grade prostate cancers. Prostate 1987, 11:327–7.PubMedGoogle Scholar
  70. 70.
    Williams K, Fernandez S, Stein X, Ishii K, Love HD, Lau YF et al. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 2005, 63:369–84.PubMedGoogle Scholar
  71. 71.
    Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP et al. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004, 10:1860–69.PubMedGoogle Scholar
  72. 72.
    Garcia-Moreno C, Mendez-Davila C, de La Piedra C, Castro-Errecaborde NA, Traba ML. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 2002, 50:241–6.PubMedGoogle Scholar
  73. 73.
    Masuda H, Fukabori Y, Nakano K, Shimizu N, Yamanaka H. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 2004, 59:101–6.PubMedGoogle Scholar
  74. 74.
    McAlhany SJ, Ressler SJ, Larsen M, Tuxhorn JA, Yang F, Dang TD et al. Promotion of angiogenesis by PS20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res 2003, 63:5859–65.PubMedGoogle Scholar
  75. 75.
    Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: Role of endothelin-1. Clin Orthop Relat Res 2003, S67–74.Google Scholar
  76. 76.
    Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. Inhibition of alpha(v)BETA3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003, 20:413–20.PubMedGoogle Scholar
  77. 77.
    Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003, 63:2096–102.PubMedGoogle Scholar
  78. 78.
    Ablin RJ, Gonder MJ, eds, Male accessory sexual glands secretions and their antithetical role in immunosurveillance, pp. 271–77. Protides of the Biological Fluids. Oxford: Pergamon Press, Ltd., Vol. 1985.Google Scholar
  79. 79.
    Wilson MJ, Sinha AA. Matrix degradation in prostate cancer. This volume, 2008.Google Scholar
  80. 80.
    Szabo KA, Ablin RJ, Singh G. Matrix metalloproteinases and the immune response. Clin Appl Immunol Rev 2004, 4:295–319.Google Scholar
  81. 81.
    Ablin RJ. PSA assays. Lancet Oncol 2000, 1:13.PubMedGoogle Scholar
  82. 82.
    Ablin RJ. A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol 1997, 123:583–94.PubMedGoogle Scholar
  83. 83.
    Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K et al. NF-κB and JNK. J Immunol 2005, 175:1197–205.PubMedGoogle Scholar
  84. 84.
    Ablin RJ, Bartkus JM, Gonder MJ, Polgar J. Factors contributing to suppression of tumor-host responsiveness, pp. 279–99. In: Human Tumour Markers-Biology and Clinical Applications. Cimino F, Birkmayer CD, Pimentel E, Klavins JV, Salvatore F, eds, Berlin: Walter de Gruyter, 1987.Google Scholar
  85. 85.
    Ablin RJ, Whyard TC. Immunobiological implications of select bioactive molecules in the prostate with A known and unknown target, pp. 148–72. In: the Prostate as an Endocrine Gland. Farnsworth WE, Ablin RJ, eds, Boca Raton, FL: CRC Press, 1990.Google Scholar
  86. 86.
    Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein “psoriasin” that is highly up-regulated in psoriatic skin. J Invest Dermatol 1991, 97:701–12.PubMedGoogle Scholar
  87. 87.
    Ruse M, Lambert A, Robinson N, Ryan D, Shon K-J, Eckert RL. S100A7, S100A10 and S100A11 are transglutaminase substrates. Biochemistry 2001, 40:3167–73.PubMedGoogle Scholar
  88. 88.
    Davies G, Watkins G, Sanders AJ, Harrison GM, Ablin RJ, Mason MD et al. A hammerhead ribozyme transgene to transglutaminase-4 increases the level of its substrate psoriasin and reduces the invasive capacity of prostate cancer cells in viro (abstract). Proc Am Assoc Cancer Res 2005, 46:5643.Google Scholar
  89. 89.
    Helbig G, Christopherson IIKW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631–38.PubMedGoogle Scholar
  90. 90.
    Ayra M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J et al. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastases. J Exp Ther Oncol 2004, 4:291–303.Google Scholar
  91. 91.
    Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD et al. CXCL12/CXCR4 signaling activates akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 2006, 66:32–48.PubMedGoogle Scholar
  92. 92.
    Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004, 4:901–09.PubMedGoogle Scholar
  93. 93.
    Loberg RD, Fridman Y, Pienta BA, Keller ET, McCauley LK, Taichman RS et al. Detection and isolation of circulating tumor cells in urologic cancers: A review. Neoplasia 2004, 6:302–09.PubMedGoogle Scholar
  94. 94.
    Davies G, Jiang WG, Mason MD. Hepatocyte growth factor/scatter factor and prostate cancer metastasis. This volume, 2008.Google Scholar
  95. 95.
    Badawi AF. Role of prostaglandin synthesis and cyclooxygenase-2 in prostate cancer and metastasis. This volume, 2008.Google Scholar
  96. 96.
    Thurairaja R, McFarlane J, Traill Z, Persad R. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 2004, 94:268–71.PubMedGoogle Scholar
  97. 97.
    Mason M, Collaborators. MRCPR4. Of bone metastases from prostate cancer: First results of the MRC PR04 trial (ISCRTN 61384873). Development 2004, 22(Suppl):4511.Google Scholar
  98. 98.
    Kim S-J, Uehara H, Yazici S, He J, Langley RR, Mathew P et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005, 65:3707–25.PubMedGoogle Scholar
  99. 99.
    Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activitivity. Cancer Res 2005, 65:4971–74.PubMedGoogle Scholar
  100. 100.
    Vanchieri C. Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004, 96:1734–35.PubMedCrossRefGoogle Scholar
  101. 101.
    Patel MI, Subbaramaiah K, Du B M, Yang P, Newman RA et al. Celecoxib inhibits prostate cancer growth: Evidence of cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005, 11:1999–2007.PubMedGoogle Scholar
  102. 102.
    Scullin, P, O’Sullivan J, Parker C. Strategies for the implementation of chemotherapy and radiotherapy. This volume 2008.Google Scholar
  103. 103.
    Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005, 65:2825–31.PubMedGoogle Scholar
  104. 104.
    Henry MD, Wen S, Silva MW, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004, 64:7995–8001.PubMedGoogle Scholar
  105. 105.
    Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes P53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 2005, 65:2872–81.PubMedGoogle Scholar
  106. 106.
    Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C. Adenovirus-mediated ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Ther 2000, 7:1307–4.PubMedGoogle Scholar
  107. 107.
    Ogata T, Teshima T, Kagawa K, Hishikawa Y, Takahashi Y, Kawaguichi A et al. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res 2005, 65:113–20.PubMedGoogle Scholar
  108. 108.
    Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. J Am Med Assoc 2005, 294:1233–9.Google Scholar
  109. 109.
    Milowsky MI, Nanus DM, Kostakoglu I, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of 90y-labeled anti-prostate specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004, 22:2522–31.PubMedGoogle Scholar
  110. 110.
    Zhao X-Y, Schneider D, Biroc SL, Parry R, Alicke B, Toy P et al. Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res 2005, 65:2846–53.PubMedGoogle Scholar
  111. 111.
    Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11:3353–62.PubMedGoogle Scholar
  112. 112.
    Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999, 161:960–3.PubMedGoogle Scholar
  113. 113.
    Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004, 25:581–611.PubMedGoogle Scholar
  114. 114.
    Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001, 61:2736–43.PubMedGoogle Scholar
  115. 115.
    Lissbrant IF, Lissbrant E, Damber J-E, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001, 35:437–52.PubMedGoogle Scholar
  116. 116.
    Halin S, Wikström P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat tumors. Cancer Res 2004, 64:5664–71.PubMedGoogle Scholar
  117. 117.
    Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA et al. Two functional epitopes of pigment epithelium-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005, 65:5144–51.PubMedGoogle Scholar
  118. 118.
    Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI et al. Inhibition of angiogenesis by the antiepidermal growth factor antibody IMCLONE C225 in androgen-independent prostate cancer growing orthotopically in nude mouse. Clin Cancer Res 2002, 8:1253–64.PubMedGoogle Scholar
  119. 119.
    Slovin SF, Kelly WK, Cohen R. Epidermal growth factor receptor (egfr) monoclonal antibody (MOAB) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): Results of a phase ib/iia study (abstract). Proc Am Soc Clin Oncol 1997, 16:311a.Google Scholar
  120. 120.
    Rosenthal M, Toner GC, Gurney H. Inhibition of the epidermal growth factor receptor (EGFR) in hormone refractory prostate cancer (HRPC): Initial results of a phase II trial of gefitinib (abstract). Proc Am Soc Clin Oncol 2003, 22:416.Google Scholar
  121. 121.
    Griffin J. The biology of signal transduction inhibition: Basic science to novel therapies. Semin Oncol 2001, 28:3–8.PubMedGoogle Scholar
  122. 122.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003, 95:458–70.PubMedGoogle Scholar
  123. 123.
    Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 2004, 63:934–39.PubMedGoogle Scholar
  124. 124.
    Rao KV, Goodin S, Capanna M. A phase II trial of imatinib mesylate in patients with PSA progession after local therapy for prostate cancer. (Abstract). Proc Am Soc Clin Oncol 2003, 22:409.Google Scholar
  125. 125.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999, 5:2891–98.PubMedGoogle Scholar
  126. 126.
    Kerr C. Second-generation antisense drug for prostate cancer. Lancet Oncol 2004, 5:646.PubMedGoogle Scholar
  127. 127.
    Hershko A, Ciechanover A. The ubiquitin system. Ann Rev Biochem 1998, 67:425–79.PubMedGoogle Scholar
  128. 128.
    Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999, 17:361–73.PubMedGoogle Scholar
  129. 129.
    Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D et al. 17-Allylamino-17-demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002, 8:986–3.PubMedGoogle Scholar
  130. 130.
    Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteasome pathway in prostate cancer cells. Cancer Res 2002, 62:2478–82.PubMedGoogle Scholar
  131. 131.
    Lokeshwar BL, MG Selzer, Zhu B, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002, 98:297–309.PubMedGoogle Scholar
  132. 132.
    Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguichi H. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-independent human prostate cancer LNCaP cells. Cancer Sci 2004, 95:271–75.PubMedGoogle Scholar
  133. 133.
    Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004, 64:5891–96.PubMedGoogle Scholar
  134. 134.
    Tokar EJ, Webber MM. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis 2005, 22:275–84.PubMedGoogle Scholar
  135. 135.
    Tokar EJ, Ancrile BB, Ablin RJ, Webber MM. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. J Exp Ther Oncol 2006, 5:323–3.PubMedGoogle Scholar
  136. 136.
    Guaiquil VH, Vera JC, Golde DW. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J Biol Chem 2001, 276:40955–961.PubMedGoogle Scholar
  137. 137.
    Ablin RJ. Lycopene: A word of caution. Am J Health-Syst Pharm 2005, 62:899.PubMedGoogle Scholar
  138. 138.
    D’Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005, 55:319–21.PubMedGoogle Scholar
  139. 139.
    Surh YJ. Chemoprevention with dietary phytochemicals. Cancer 2003, 3:768–80.PubMedGoogle Scholar
  140. 140.
    Li Y, Che M, Bhagat S, Ellis K-L, Kucuk O, Doerge DR et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004, 6:354–63.PubMedGoogle Scholar
  141. 141.
    Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC et al. Genistein inhibits P39 map kinase activation, matrix metalloproteinases type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005, 65:3470–78.PubMedGoogle Scholar
  142. 142.
    Cha T-L, Qiu L, Chen C-T, Wen Y, Hung M-C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005, 65:2287–95.PubMedGoogle Scholar
  143. 143.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med 2004, 351:1502–2.Google Scholar
  144. 144.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Eng J Med 2004, 351:1513–20.Google Scholar
  145. 145.
    Huggins CB, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 143:209–3.Google Scholar
  146. 146.
    Ehrlich P. Ueber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909, 5:273–90.Google Scholar
  147. 147.
    Burnet FM. Cancer: A biological approach. Br Med J 1957, 1:779–86.PubMedCrossRefGoogle Scholar
  148. 148.
    Ablin RJ. Immunotherapy for prostatic cancer. Previous and prospective considerations. Oncology 1975, 31:177–202.Google Scholar
  149. 149.
    Hawkins LK, Lemonine NR, Kim D. Oncolytic biotherapy: A novel therapeutic platform. Lancet Oncol 2002, 3:17–26.PubMedGoogle Scholar
  150. 150.
    Kaminski JM, Summers JB, Ward MW, Huber MR, Minev B. Immunotherapy and prostate cancer. Cancer Treat Rev 2003, 29:199–09.PubMedGoogle Scholar
  151. 151.
    Markiewicz MA, Kast WM. Advances in immunotherapy for prostate cancer. Adv Cancer Res 2003, 87:159–94.PubMedGoogle Scholar
  152. 152.
    Xue B-H, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997, 30:73–8.PubMedGoogle Scholar
  153. 153.
    Perambakam S, Xue B-H, Sosman JA, Peace DJ. Induction of TC2 cells with specificity for prostatate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2002, 51:263–70.PubMedGoogle Scholar
  154. 154.
    Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000, 164:5508–14.PubMedGoogle Scholar
  155. 155.
    Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulated CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409–17.PubMedGoogle Scholar
  156. 156.
    Ablin RJ. An appreciation of the concept of cryoimmunology, pp. 136–54. In: Percutaneous Prostate Cryoablation. Onik GM, Rubinsky B, Watson G, Ablin RJ, eds, St. Louis, MO: Quality Medical Publishing, Inc, 1995.Google Scholar
  157. 157.
    Ablin RJ, Bradley PF. Immunological aspects of cryosurgery, pp. 77–99. In: Cryosurgery of the Maxillofacial Region, Vol. 1. Bradley PF, ed., Boca Raton, FL: CRC Press, 1986.Google Scholar
  158. 158.
    Ikekawa S, Ishihara K, Tanaka S, Ikeda S. Basic studies of cryochemotherapy in a murine tumor system. Cryobiology 1985, 22:477–83.PubMedGoogle Scholar
  159. 159.
    Mouraviev V, Prochorov G, Ablin RJ. Cryoimmunochemotherapy for advanced prostate cancer (abstract). Int J Mol Med 2000, 6(Suppl 1):S30.Google Scholar
  160. 160.
    Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J. Cryosurgery in aggressive, benign, and low-grade malignant tumours. Lancet Oncol 2005, 6:25–34.PubMedGoogle Scholar
  161. 161.
    Callstrom M.,Cryoablation treatment helps diminish pain of bone cancer (Abstract). Society of Interventional Radiology, 30th Annual Meeting. New Orleans, LA. 2005.Google Scholar
  162. 162.
    Ablin RJ, Soanes WA, Gonder MJ. Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology 1971, 8:271–76.Google Scholar
  163. 163.
    Ablin RJ. The current status and the prospect for cryoimmunotherapy. Low Temp Med 2003, 29:46–9.Google Scholar
  164. 164.
    Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme TL et al. Therapeutic effects of adoptive splenocyte transfer following in situ ADIL-12 gene therapy in a mouse model of prostate cancer. Cancer Gene Ther 2006, 13:91–8.PubMedGoogle Scholar
  165. 165.
    Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004, 114:1774–81.PubMedGoogle Scholar
  166. 166.
    Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003, 63:2470–76.PubMedGoogle Scholar
  167. 167.
    Eshhar Z. Tumor-specific T bodies: Towards clinical application. Cancer Immunol Immunother 1997, 45:131–6.PubMedGoogle Scholar
  168. 168.
    Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999, 48:346–52.PubMedGoogle Scholar
  169. 169.
    Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999, 20:576–82.PubMedGoogle Scholar
  170. 170.
    Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003, 131:254–63.PubMedGoogle Scholar
  171. 171.
    NCI Launches Biorepository for Prostate Cancer. NIH News, November 7, 2005. ( Accessed November 7, 2005.Google Scholar
  172. 172.
    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011–15.PubMedGoogle Scholar
  173. 173.
    Botchkina GI, Kim RH, Botchkina IL, Kirshenbaum A, Frischer Z, Adler HL. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res 2005, 11:3243–49.PubMedGoogle Scholar
  174. 174.
    Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503–21.PubMedGoogle Scholar
  175. 175.
    Pipes BL, Ablin RJ. Cancer stem cells revisited. Curr Oncol 2005, 12:134–5.Google Scholar
  176. 176.
    Bonkhoff H, Remberger K. Differentiation pathways and histogenic aspects of normal and abnormal prostate growth: A stem cell model. Prostate 1996, 28:98–106.PubMedGoogle Scholar
  177. 177.
    Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989, 2:33–50.PubMedGoogle Scholar
  178. 178.
    Van Leenders G, Schalken JA. Stem cell differentiation within the human prostate epithelium: Implications for prostate carcinogenesis. BJU Intl 2001, 8:35–42.Google Scholar
  179. 179.
    Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on α 2β 1-integrin expression. J Cell Sci 2001, 114:3865–72.PubMedGoogle Scholar
  180. 180.
    Schalken JA, Van Leenders G. Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003, 62:11–20.PubMedGoogle Scholar
  181. 181.
    Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843–50.PubMedGoogle Scholar
  182. 182.
    Taipale J, Beachy PA. The hedgehog and wnt signalling pathways in cancer. Nature 2001, 411:349–54.PubMedGoogle Scholar
  183. 183.
    Schmelz M, Moll R, Hesse U, Prasad AR, Gandolfi JA, Bartholdi M, Cress AE. Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol 2005, 84:341–54.PubMedGoogle Scholar
  184. 184.
    Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946–51.PubMedGoogle Scholar
  185. 185.
    Ablin RJ, Bhatti RA. Tumor-associated immunity in prostate cancer, pp. 183–204. In: Prostatic Cancer, Ablin RJ, ed., New York: Marcel Dekker, Inc, 1981.Google Scholar
  186. 186.
    Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D et al. Autoantibody signatures in prostate cancer. N Eng J Med 2005, 353:1224–35.Google Scholar
  187. 187.
    Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VA, George NJ et al. Novel method for the isolation and characterization of the putative prostatic stem cell. Cytometry 2003, A: 54:89–99.PubMedGoogle Scholar
  188. 188.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105–1.PubMedGoogle Scholar
  189. 189.
    Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005, 174:3798–807.PubMedGoogle Scholar
  190. 190.
    Biroccio A, Leonetti C. Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocr Relat Cancer 2004, 11:407–21.PubMedGoogle Scholar
  191. 191.
    He X, Tsang TC, Pipes BP, Ablin RJ, Harris DH. A stem cell fusion model of carcinogenesis. J Exp Ther Oncol 2005, 5:101–9.PubMedGoogle Scholar
  192. 192.
    Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005, 4:1171–5.PubMedGoogle Scholar
  193. 193.
    Pipes BL, Ablin RJ. Cancer: Evasion of stem cell senescence. Submitted.Google Scholar
  194. 194.
    Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S et al. Small cell carcinoma of the prostate: An immunohistochemical study. Am J Surg Pathol 2006, 30:705–12.PubMedGoogle Scholar
  195. 195.
    Slovin SF. Neuroendocrine differentiation in prostate cancer: A sheep in wolf’s clothing. Nat Clin Pract Urol 2006, 3:138–44.PubMedGoogle Scholar
  196. 196.
    Papandreou CN, Daliani DD et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002, 20:3072–80.PubMedGoogle Scholar
  197. 197.
    Zaviacic M. the Human Female Prostate. From Vestigial Skene’s Paraurethral Glands and Ducts to Woman’s Functional Prostate. Bratislava: Slovak Academic Press, 1999. 171 p.Google Scholar
  198. 198.
    Zaviacic M, Ablin RJ. The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in woman and reasons for using the term “prostate” in the human female. Histol Histopathol 2000, 15:131–42.PubMedGoogle Scholar
  199. 199.
    Sloboda J, Zaviacic M, Jakubovsky J, Hammar E, Johnson J. Metastasizing adenocarcioma of the female prostate (skene’s paraurethral glands). Pathol Res Pract 1998, 194:129–36.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Richard J. Ablin
    • 1
  • Malcolm D. Mason
    • 2
  1. 1.Department of ImmunobiologyUniversity of Arizona College of Medicine and the Arizona Cancer CenterTucsonUSA
  2. 2.Section of Oncology and Palliative MedicineUniversity of Wales College of Medicine, Velindre HospitalCardiffUK

Personalised recommendations